The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
TCT 2021 | Relationship between IL-15 serum concentrations & CD19 CAR T-cell therapy
Jordan Gauthier, MD, MSc, Fred Hutchinson Cancer Research Center, Seattle, WA, discusses the relationship between interleukin-15 (IL-15) serum concentrations, anti-tumor efficacy, and in vivo CAR T-cell kinetics in patients treated with anti-CD19 CAR T-cell therapies. IL-15 serum concentrations are associated with higher probabilities of response and higher CAR T-cell in vivo expansion and persistence. This interview took place during the Transplantation & Cellular Therapy (TCT) 2021 Meetings.
Disclosures
Consulting: JMP, Eusapharma, Multerra Bio
